NR565 ADVANCED PHARMACOLOGY MIDTERM EDAPT
REVIEW 2026/2027 | Already Rated A | Chamberlain College
Complete Guide | Pass Guaranteed
Edapt Module 1: Pharmacokinetics & Pharmacodynamics (20 Questions)
Q1
Clinical Scenario: A 68-year-old male with chronic heart failure and reduced ejection
fraction is prescribed oral digoxin 0.25 mg daily. He has normal hepatic function but his
creatinine clearance is 35 mL/min. His serum albumin is 3.2 g/dL (normal 3.5-5.0). After
5 days of therapy, his digoxin level is subtherapeutic.
Question: Which pharmacokinetic parameter is most significantly altered in this patient,
necessitating a dosing adjustment?
A. First-pass metabolism due to decreased hepatic blood flow
B. Volume of distribution due to decreased protein binding and altered tissue
distribution
C. Bioavailability due to increased gastrointestinal motility
D. Hepatic clearance due to decreased CYP450 enzyme activity
Correct Answer: B
Rationale: Digoxin has a large volume of distribution (Vd) primarily distributed to
skeletal muscle and tissues. In patients with low serum albumin (3.2 g/dL), there is
,decreased protein binding, but more importantly, the Vd of digoxin is significantly
reduced in patients with decreased lean body mass and renal dysfunction. However, the
primary issue here is that digoxin is really excreted unchanged by the kidneys (60-80%).
With a CrCl of 35 mL/min, renal clearance is markedly decreased, leading to drug
accumulation. The question asks about the parameter necessitating adjustment. The
decreased renal function reduces clearance, requiring dose reduction. The decreased
albumin actually increases free fraction but digoxin is not highly protein bound
(20-30%). The key concept from Edapt is that in renal impairment, maintenance doses
of renally cleared drugs must be reduced. Option A is incorrect because digoxin
undergoes minimal hepatic metabolism. Option C is incorrect because bioavailability is
not primarily affected by GI motility in this context. Option D is incorrect because
hepatic clearance is not the primary route for digoxin. The correct understanding is that
reduced renal clearance necessitates dose adjustment to prevent toxicity despite the
initial subtherapeutic level mentioned (which may reflect timing of level drawn).
Q2
Clinical Scenario: A 45-year-old female with complex partial seizures is started on
phenytoin. The prescriber orders an oral loading dose of 15 mg/kg followed by a
maintenance dose of 5 mg/kg/day. The patient weighs 60 kg.
Question: The nurse practitioner understands that the rationale for using a loading dose
is based on which pharmacokinetic principle?
A. To immediately achieve steady-state concentration without waiting 4-5 half-lives
B. To saturate plasma protein binding sites and increase free drug concentration
C. To overcome first-pass metabolism and increase bioavailability
,D. To induce hepatic enzymes and enhance subsequent drug metabolism
Correct Answer: A
Rationale: The fundamental principle of loading doses is to achieve therapeutic
concentrations rapidly without waiting the 4-5 half-lives required to reach steady state
with maintenance dosing alone. Phenytoin has a long half-life (12-36 hours, average 22
hours), so waiting for steady state would take 3-5 days. The loading dose formula
(Loading Dose = Vd × Target Concentration) allows immediate therapeutic levels. Option
B is incorrect because while phenytoin is highly protein bound (90%), saturating binding
sites is not the purpose of loading doses and would actually increase toxicity risk.
Option C is incorrect because loading doses do not overcome first-pass metabolism;
phenytoin has good bioavailability (90%). Option D is incorrect because enzyme
induction occurs over days to weeks, not with a single loading dose, and this would
actually reduce subsequent drug levels. This question reflects Edapt's emphasis on
applying pharmacokinetic calculations to clinical practice.
Q3
Clinical Scenario: A 72-year-old male with atrial fibrillation is prescribed warfarin 5 mg
daily. His INR after 3 days is 1.2 (goal 2.0-3.0). The prescriber increases the dose to 7.5
mg daily. After 5 more days, his INR is 4.8.
Question: Which pharmacokinetic concept best explains this supratherapeutic
response?
A. Zero-order kinetics causing drug accumulation at higher doses
B. Delayed distribution phase leading to initial underestimation of drug effect
, C. Drug interaction at CYP2C9 increasing metabolism
D. Narrow therapeutic index requiring precise individualization
Correct Answer: B
Rationale: Warfarin exhibits a delayed pharmacodynamic effect due to the long half-life
of pre-existing clotting factors (Factor II has t½ of 60 hours). The full anticoagulant
effect is not seen for 3-5 days after initiation or dose change. The initial INR of 1.2
reflected residual functional clotting factors, not steady-state warfarin effect. Increasing
the dose before steady state was achieved resulted in accumulation and
supratherapeutic INR. This demonstrates the Edapt concept that pharmacodynamic
effects may lag behind pharmacokinetic steady state. Option A is incorrect because
warfarin follows first-order kinetics. Option C is incorrect because an interaction
increasing metabolism would decrease INR, not increase it. Option D, while true that
warfarin has a narrow therapeutic index, does not explain the delayed supratherapeutic
response—it is the reason for careful monitoring, not the explanation for the overshoot.
Q4
Clinical Scenario: A 55-year-old female with hypertension is prescribed propranolol 40
mg twice daily. She has asthma and experiences bronchospasm after the first dose.
Question: This adverse effect is best explained by which pharmacodynamic principle?
A. Non-selective beta-blockade causing unopposed alpha-adrenergic stimulation
B. Blockade of beta-2 receptors in bronchial smooth muscle preventing bronchodilation
C. Partial agonist activity at beta-1 receptors causing reflex tachycardia
REVIEW 2026/2027 | Already Rated A | Chamberlain College
Complete Guide | Pass Guaranteed
Edapt Module 1: Pharmacokinetics & Pharmacodynamics (20 Questions)
Q1
Clinical Scenario: A 68-year-old male with chronic heart failure and reduced ejection
fraction is prescribed oral digoxin 0.25 mg daily. He has normal hepatic function but his
creatinine clearance is 35 mL/min. His serum albumin is 3.2 g/dL (normal 3.5-5.0). After
5 days of therapy, his digoxin level is subtherapeutic.
Question: Which pharmacokinetic parameter is most significantly altered in this patient,
necessitating a dosing adjustment?
A. First-pass metabolism due to decreased hepatic blood flow
B. Volume of distribution due to decreased protein binding and altered tissue
distribution
C. Bioavailability due to increased gastrointestinal motility
D. Hepatic clearance due to decreased CYP450 enzyme activity
Correct Answer: B
Rationale: Digoxin has a large volume of distribution (Vd) primarily distributed to
skeletal muscle and tissues. In patients with low serum albumin (3.2 g/dL), there is
,decreased protein binding, but more importantly, the Vd of digoxin is significantly
reduced in patients with decreased lean body mass and renal dysfunction. However, the
primary issue here is that digoxin is really excreted unchanged by the kidneys (60-80%).
With a CrCl of 35 mL/min, renal clearance is markedly decreased, leading to drug
accumulation. The question asks about the parameter necessitating adjustment. The
decreased renal function reduces clearance, requiring dose reduction. The decreased
albumin actually increases free fraction but digoxin is not highly protein bound
(20-30%). The key concept from Edapt is that in renal impairment, maintenance doses
of renally cleared drugs must be reduced. Option A is incorrect because digoxin
undergoes minimal hepatic metabolism. Option C is incorrect because bioavailability is
not primarily affected by GI motility in this context. Option D is incorrect because
hepatic clearance is not the primary route for digoxin. The correct understanding is that
reduced renal clearance necessitates dose adjustment to prevent toxicity despite the
initial subtherapeutic level mentioned (which may reflect timing of level drawn).
Q2
Clinical Scenario: A 45-year-old female with complex partial seizures is started on
phenytoin. The prescriber orders an oral loading dose of 15 mg/kg followed by a
maintenance dose of 5 mg/kg/day. The patient weighs 60 kg.
Question: The nurse practitioner understands that the rationale for using a loading dose
is based on which pharmacokinetic principle?
A. To immediately achieve steady-state concentration without waiting 4-5 half-lives
B. To saturate plasma protein binding sites and increase free drug concentration
C. To overcome first-pass metabolism and increase bioavailability
,D. To induce hepatic enzymes and enhance subsequent drug metabolism
Correct Answer: A
Rationale: The fundamental principle of loading doses is to achieve therapeutic
concentrations rapidly without waiting the 4-5 half-lives required to reach steady state
with maintenance dosing alone. Phenytoin has a long half-life (12-36 hours, average 22
hours), so waiting for steady state would take 3-5 days. The loading dose formula
(Loading Dose = Vd × Target Concentration) allows immediate therapeutic levels. Option
B is incorrect because while phenytoin is highly protein bound (90%), saturating binding
sites is not the purpose of loading doses and would actually increase toxicity risk.
Option C is incorrect because loading doses do not overcome first-pass metabolism;
phenytoin has good bioavailability (90%). Option D is incorrect because enzyme
induction occurs over days to weeks, not with a single loading dose, and this would
actually reduce subsequent drug levels. This question reflects Edapt's emphasis on
applying pharmacokinetic calculations to clinical practice.
Q3
Clinical Scenario: A 72-year-old male with atrial fibrillation is prescribed warfarin 5 mg
daily. His INR after 3 days is 1.2 (goal 2.0-3.0). The prescriber increases the dose to 7.5
mg daily. After 5 more days, his INR is 4.8.
Question: Which pharmacokinetic concept best explains this supratherapeutic
response?
A. Zero-order kinetics causing drug accumulation at higher doses
B. Delayed distribution phase leading to initial underestimation of drug effect
, C. Drug interaction at CYP2C9 increasing metabolism
D. Narrow therapeutic index requiring precise individualization
Correct Answer: B
Rationale: Warfarin exhibits a delayed pharmacodynamic effect due to the long half-life
of pre-existing clotting factors (Factor II has t½ of 60 hours). The full anticoagulant
effect is not seen for 3-5 days after initiation or dose change. The initial INR of 1.2
reflected residual functional clotting factors, not steady-state warfarin effect. Increasing
the dose before steady state was achieved resulted in accumulation and
supratherapeutic INR. This demonstrates the Edapt concept that pharmacodynamic
effects may lag behind pharmacokinetic steady state. Option A is incorrect because
warfarin follows first-order kinetics. Option C is incorrect because an interaction
increasing metabolism would decrease INR, not increase it. Option D, while true that
warfarin has a narrow therapeutic index, does not explain the delayed supratherapeutic
response—it is the reason for careful monitoring, not the explanation for the overshoot.
Q4
Clinical Scenario: A 55-year-old female with hypertension is prescribed propranolol 40
mg twice daily. She has asthma and experiences bronchospasm after the first dose.
Question: This adverse effect is best explained by which pharmacodynamic principle?
A. Non-selective beta-blockade causing unopposed alpha-adrenergic stimulation
B. Blockade of beta-2 receptors in bronchial smooth muscle preventing bronchodilation
C. Partial agonist activity at beta-1 receptors causing reflex tachycardia
